FATE
Fate Therapeutics Inc
2.30$
+0.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1,968.8% | -2,186.0% | -1,732.5% | -477.1% | -957.0% | -1,494.6% | -2,075.4% | -1,289.3% | -1,400.0% | -1,703.0% | -2,372.7% | -1,125.6% | -1,570.5% | |
| 243.8% | 291.5% | 250.4% | 69.7% | 149.9% | 258.8% | 204.6% | 171.9% | 185.4% | 223.7% | 165.2% | 133.5% | 172.8% | |
| 519.8% | 565.3% | 570.4% | 142.2% | 382.7% | 490.3% | 453.1% | 375.1% | 279.2% | 403.8% | 302.5% | 169.0% | 274.8% | |
| -145.1% | -11.3% | 31.9% | -56.0% | 101.8% | -102.6% | -329.8% | 3.8% | 28.9% | 77.1% | -459.1% | -3.1% | -68.8% | |
| 29.1% | 10.8% | 4.5% | 0.8% | 16.1% | 5.3% | 73.4% | 71.4% | 126.5% | 87.1% | 18.4% | 3.8% | 57.2% | |
| 1,276.0% | 2,706.0% | 899.4% | -788.1% | 828.3% | 1,226.7% | 2,619.6% | 1,027.3% | 1,221.8% | 2,018.3% | 1,815.8% | 699.2% | 1,341.0% | |
| – | -10.7% | – | -9.8% | 21.7% | -35.8% | – | – | – | – | – | – | – | |
| 0.0% | -10.7% | 4,960.4% | 18.8% | 0.0% | 168.3% | 0.0% | 69.5% | 142.2% | 123.4% | – | 83.4% | – | |
| -692.8% | 509.3% | 4,127.4% | -1,246.4% | 32.3% | -99.6% | 544.1% | -192.5% | -36.0% | 438.7% | -557.0% | -343.0% | -138.6% | |
| -1,997.8% | -2,196.8% | -1,736.9% | -477.8% | -973.1% | -1,499.8% | -2,148.9% | -1,360.7% | -1,526.5% | -1,790.1% | -2,391.1% | -1,129.4% | -1,627.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.